X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, VIB acquired Oxurion's preclinical oncology asset and will use the upfront in the development of THR-149, being evaluated in a Phase 2 clinical trial as a potential treatment for of diabetic macular edema.
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Oxurion
Deal Size: $32.4 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement July 24, 2023
Details:
XVR013 targets a conserved region in the spike S2 subunit that is essential for viral entry. It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.
Lead Product(s): XVR013
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR013
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: ExeVir Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine, targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks immunosuppressive biologic effects of IL-27.
Lead Product(s): SRF388
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Surface Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials.
Lead Product(s): VHH72-Fc antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: XVR011
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ExeVir Bio
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 16, 2021
Details:
The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus.
Lead Product(s): Antibody-based drug
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
